MiMedx Group/$MDXG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Ticker
- $MDXG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 808
- Headquarters
- Marietta, United States
- Website
- www.mimedx.com
MiMedx Group Metrics
BasicAdvanced
$638M
103.97
$0.04
1.41
-
Price and volume
Market cap
$638M
Beta
1.41
52-week high
$7.97
52-week low
$3.03
Average daily volume
1.3M
Financial strength
Current ratio
5.334
Quick ratio
4.601
Long term debt to equity
0.073
Total debt to equity
0.08
Interest coverage (TTM)
5.41%
Profitability
EBITDA (TTM)
20.411
Gross margin (TTM)
78.85%
Net profit margin (TTM)
1.76%
Operating margin (TTM)
2.46%
Effective tax rate (TTM)
45.91%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
1.91%
Return on equity (TTM)
2.88%
Valuation
Price to earnings (TTM)
103.969
Price to revenue (TTM)
1.826
Price to book
2.95
Price to tangible book (TTM)
3.46
Price to free cash flow (TTM)
14.599
Free cash flow yield (TTM)
6.85%
Free cash flow per share (TTM)
0.3
Growth
Revenue change (TTM)
-2.36%
Earnings per share change (TTM)
-80.07%
3-year revenue growth (CAGR)
6.38%
10-year revenue growth (CAGR)
5.32%
3-year earnings per share growth (CAGR)
-37.14%
10-year earnings per share growth (CAGR)
-14.88%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
Analyst projections of the future price of MiMedx Group stock.
Bulls say / Bears say
Surgical sales grew 15% year on year in Q2 2026, extending the franchise’s run of double-digit growth and helping offset weakness in wound care. (GlobeNewswire)
Wound volumes rose 22% sequentially in Q2, including stronger activity in wound care centres. This may indicate the business is beginning to adapt to the new reimbursement environment, although sales remain well below last year. (GlobeNewswire)
MiMedx expects its Sanara acquisition to take combined revenue above $400 million and adjusted EBITDA margins above 20% in 2027, offering a route to greater scale and a broader surgical business. (Yahoo Finance)
Medicare reimbursement changes drove a 61% year-on-year fall in Q2 wound sales and a 35% decline in total sales. Management expects the new payment framework to remain in place into 2027, keeping pressure on the core wound business. (The Motley Fool)
The sales shock has hit profitability: Q2 adjusted EBITDA was a loss of $8 million, while gross margin fell to 69% from 81% a year earlier. That leaves execution on cost cuts and a return to profit uncertain. (Yahoo Finance)
The FTC has issued a second request in the MiMedx–Sanara merger review, extending the waiting period. A delay could push back the deal’s expected contribution and synergies. (EveryTicker)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
MiMedx Group News
AllArticlesVideos
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire1 month ago
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire3 months ago
MiMedx Group Q2 Earnings Call Highlights
MarketBeat3 months ago
Funds containing MiMedx Group
Fund name | Fund size | $MDXG weighting |
|---|---|---|
iShares Ageing Population£AGES | $953M | 0.05% |
iShares Ageing Population$AGED | $953M | 0.05% |
iShares Ageing Population€AGED | $903M | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.